XXXX full our them I us quarter call financial operating financial thank hope this year Good our and update you morning, review year on you, able for today. and Bob. earlier We fiscal to briefly. business results Thank fourth joining been issued and you've and morning,
onset, significant these XX XXXX to validating for pleased Fiscal unprecedented marked was ended many and meeting am team of with the in report Enzo, fiscal XXXX times. accomplishments. July extraordinary proved a which our At I the its strength as challenges year Enzo
reflect a and pandemic we events COVID-XX lasting the XXXX we increasingly long priority will on present, are health As remain of recognizing that be some time. care to for the
rates, the and vaccination masking to ongoing. leisure some to Enzo enforcement travel at be fluid testing level is and environment. their return this increase employees offices, and are likely populations prepared We for committed increases loosens, As need remain for of
vaccinations potency have as will and More a and After masking testing variant emergent even adherence with slowdown should to solutions its of bit needs to the We when this greater moderate demonstrates precautions. of more arise. The other with course remain ready to rebounded. of flexible cost greater challenges introduce intend help vaccine summer, new rates the infection in to to the a meet they ability disease, of recent vigor this and careful virus mutate. efficient, new any these increase
inherent medical innovation. demonstrated also and on are innovation go-forward committed scientific at of capitalizing a the to We strategy, to with our forefront ability remain
as targeting As channels, for new and the schools, venues we testing. market evolved, on new business including has pharmacies have focused
as diagnostic areas, has extending COVID-XX such to hundreds our GENFLEX women's thousands year We specimens respiratory of are platform transmitted infections, past gastrointestinal diseases. upper and other health, processed infections this of sexually for that
platform. additional tests for approvals our to in the are a We regulatory of GENFLEX process of number
in pipeline Our test available XX-K the of is today. released
lives. impact changes resulted vast is alike, the and practitioners in and care peoples for pandemic patients fresh health in in still The very
office physician depending hospital operational, on are and and geography test vary can visits demographics. and greatly services inpatient utilization outpatient returning levels are While
molecular enhancements our year, past COVID-XX on and platform the of developed capitalized and improvements hundreds we specimens. During GENFLEX of to thousands process
shift more at demand point now direct for testing in setting, recognize facilities. in specifically immediate a molecular and We of the also care
We are of future point central the a strategic direct-to-consumer care lab, outside testing actively of in and including involved development and of platforms commercialization offerings.
Point capabilities, for open required of hour these Enzo development, and within types affordable we validation performance future proof-of-concept simple and accurate systems. diagnostics have and that mostly of care internally results. proprietary procedures the a of path half Using rapid, generated commercialization of a strategies
study was development LoopRNA featured and the year, interpretation, collaborators our In of with addition publication capabilities. technology, improved in gene novel work to our scientists. allows opportunities, use potentially Enzo's better targeting Earlier probe independent from research an LoopRNA scientific derived molecular structure of for medical for conjunction Enzo in drug our diagnostic accelerated this
sensitivity publication higher products reflecting leading in when The details to improvements lower to and commercially available hybridization, insight background services. compared and noise
scientific within This structure. allows better a research destroying interpretation, without improved sequence drug genetic and single the a identify medical uniquely cell probes advance development accelerated capabilities. for Enzo's cell
positives human to also negatives reduce We RNA detection updates on in provide based our the papillomavirus. on the risk for of intend infections earlier false It coming and may LoopRNA false months. technology such as
supporting to company, to integrated During vertically we new of fiscal further diagnostics paradigm. the strategy a XXXX validated strength a industry transition our more
and eye important approach an enabled with us has an effectiveness efficiencies, niche carve a on innovator and as scientific growing Our out to affordability.
a Enzo financials, will of point the solid Bench, summary, Quickly, highlights. discuss fourth year shortly, and at both a period which execution, represented financial our like operationally financially. fiscal briefly Looking to CFO, David to our few detail and in I'd quarter
revenues total in the million, revenue increase XX% the from growth year-over-year. of which this XX% and $XX.X for year-over-year were XXXX of an were XX%, year respectively. quarter $XX and this year XX% product year, Fiscal $XXX.X Our achieved We services million up both million, impressive is the segments revenue prior. was the growth
we $XX reported million to several for efficiencies in the support These we and team's proud approximately quarters continue on the of full we generate are the We to were focus also continued success. savings year. and initiatives, cost throughout extremely have trend able results
In quarter of the at the Enzo briefly detection for extraction of variants. genetic on system an the including its rapid of Looking the July, received year. test for Emergency highlights the SARS-CoV-X, expansion coronavirus Authorization full proprietary company's method its Use and fourth
to EUA Enzo's The laboratories the a instrument. process more or immediately faster more enabling test XX%, extraction over enables hour use by single one to time runs on reduce than running
that expanded winning diagnostic edge separates our technology. in EUA example products the of too Our from the and success companies Enzo of and cutting differentiation testing on another me many services is the keeps
value long-term benefit to remains anticipate as will meaningful the opportunities, reimbursement Our and core headwinds development provide we on of focus which in the customers remain application high environment.
a achieved The higher tests. spectrum key the integrated of being by to of XXXX and our margins are molecular This model testing XXXX other and vertically is expanded COVID-XX strategy. to our
rapid CLX New travel. new to New a with required tests cloud-based for that provide COVID-XX locations In June, in a of Enzo developer to York and international are Health, performed solutions, access testing collaboration Jersey for PCR
service, COVID-XX than Health's Using receive in and travel this travelers includes TrustAssure by in XX using immediately partners Platform, PCR can tests which more countries. CLX Testing schedule testing online results Global of advance
add opportunities as can part scale standpoint, remain that existing blueprint. engaged testing and These broader possible for will our From activities value to include market. we regarding and and complement across fresh a we services of development our seek the partnerships tuck-in growth proprietary products business business acquisitions
point and a campus. from GMP of Farmingdale and laboratory include services, four consolidated our R&D, we campus manufacturing, Logistically on sales capabilities, all view, to have buildings within manufacturing clinical Enzo's marketing adjacent
Ann Arbor, of our This the summer integration this finalized was Michigan transfer complete well. includes facility, which manufacturing as
of this efficiencies of in begin to the We initiative be accretive the expect XXXX. second see half to
Now manufactured the under the kit, Sample FDA received Emergency GMP April, is Authorization. now full for turning year our for Enzo distribution to AMPICOLLECT which Use In highlights. Collection clearance under
which protocols The AMPICOLLECT collection as United kit to winter collection further QX we increase for is the this - testing utilize COVID-XX for as available expect from tend is to sample testing expected levels. in sample States, now
that impact results. guidance developers COVID-XX the on platform FDA calling GENFLEX viral assess new mutations testing indicate met showed results March, In of the for its testing to company
released evaluate September, impact tests variants have to on the of makers additional certain performance. conditions test in for Emergency received authorization the requiring FDA test of update and And labeling Use Authorizations, that SARS-CoV-X authorized
importance updating evaluate test test the our of the on and to viral of continuously these needs realize mutations impact the performance. We
initial In pooled samples and GENFLEX of company SARS-CoV-X. EUA January, in the detection Enzo up these test received containing system, an high expansion tests XXXX platform authorizing of its for swab platforms, five its on use its EUA received including the the specimens utilizing Enzo's three from July platform. individual different throughput AMPIPROBE to FDA, proprietary automated of proprietary SARS-CoV-X the with The
Tagliaferri. a well directors regulatory medical Both highly announced operational business In the in of November with areas, appointment B. Ian its to clinical Dr. Mary as Enzo new Walters industry Board, experience respected and as affairs. R&D, of development, two Dr. XXXX, of are including and range leaders
In XXXX, enables announced molecular COVID-XX we launched antibody company order online for to a major the platform when tests, consumers including milestone This authorized we physician and GoTestMeNow. lab October directly tests.
expand future we gastrointestinal platform infections health panels. [ph] panels testing access GoTestMe include upper now this offerings planning and panels, fall, women's Later to to are the to offer for for planning and transmitted to are sexually respiratory
testing consumer be that access will and believe demand services. tests consumers these in reflect attractive seeking an transition We accessing direct these of offerings to to ease expanded important for
microplate industrial has portable deem focused ultimately, been complete to very for XXXX, an in extremely And busy with that important device a of and company and, enables reader future. medicine, immunoassays a CRO a care diagnostics offer the It an small, This year. point use in the customers. providing very Enzo affordable, molecular in solution academic, and to the and company's new opportunities October launched area we
want This unwavering I Enzo been we to and amazing of a behalf during done have of recognize this the and they to management has for our work strength we the time. that grateful employees all year their challenging On extremely today. reiterate commitment team, are to
our in on strategic are in ability it our ahead. vision year confident We to the and execute
transitions believe we in integrated, company. have flexible foundation team XXXX vertically laid the have diagnostics to the pivoted Enzo and has We many a made solid from which important
of to the served objectives, important and well David, and us it's XXXX discipline highlight core passing the a call today. Enzo in remain which to Before over focus company's fiscal
integrated transforming an diagnostics we to on genomic end focusing and molecular company, analysis. and into end solutions First, are product
platforms to the in and four out building sector. technologies are key address we diagnostics value enhanced our Second,
Third, implement measures our we to cost our growth. in we in for bring needs. market the with investing line infrastructure And structure better continue fourth, are building and efficiency to
we to management's these across is say It as today I stress can confidently executed have all these critical objectives, four pillars. commitment of to
management objectives XXXX. core to outlined following XXXX support be of the months for guiding the As team in have with the the we the prepared fiscal fiscal ago, several principles Board
Suffolk commercialization the COVID-XX with strategic of in that to First, done a of County government as with we alignment, regionality provider associations as industry being testing as of of leaders well in accelerate of Long the other partnering business proprietary to key Enzo's platforms. associations Island have terms nature, [ph]
Second, for diagnostics the platforms we and expanding on expansion, our focusing purposes and business product and service GENFLEX channels. expanding test platform menu new efficient on cost are leveraging
third, on financial and efficiency operational the And measures, of the expanded building achievements XXXX.
attacking future see, you As we with the and can determination are vigor.
the year accomplish, alive are The we we remarkable what And our have to fronts. what been well, really and expect The Enzo spirit knows a year believe, so of we optimism no about innovation bounds. done many is and numerous. on has opportunities
detailed give to and you With will insights, CFO, XXXX call Dave? of the a turn the review over our fourth to I quarter financials. fiscal like David these who more would little Bench,
